A pharma ticker's Phase 3 trial reads as de-risked — failure probability well below the base rate.
A pharma company where our Bayesian engine found the signal evidence is pointing toward trial success. Enrollment is ahead of schedule, the endpoint hasn't been amended, the mechanism is well-validated. On a positive readout the stock typically gains 20-50%; the market is under-pricing the probability of that outcome.
Same Bayesian machinery as PHARMA_FAILURE_HIGH, operating at the other end of the probability distribution. When multiple positive signals stack up, the posterior tilts toward success well before the readout — but the options market typically waits for the binary event itself.
Even de-risked Phase 3 trials have ~15-25% failure probability. The pattern works on expected value across many such bets, not on conviction about any single name. Sizing per position and diversification across pharma catalysts matters.